Profound Medical Corp.
NASDAQ:PROF
4.98 (USD) • At close May 8, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 10.68 | 7.199 | 6.681 | 6.873 | 7.304 | 4.232 | 1.911 | 3.9 | 0 | 0 | 0 |
| Cost of Revenue
| 3.643 | 2.817 | 3.66 | 3.921 | 3.83 | 1.808 | 1.306 | 2.411 | 0.187 | 0.119 | 0 |
| Gross Profit
| 7.037 | 4.382 | 3.021 | 2.952 | 3.474 | 2.424 | 0.605 | 1.489 | -0.187 | -0.119 | 0 |
| Gross Profit Ratio
| 0.659 | 0.609 | 0.452 | 0.43 | 0.476 | 0.573 | 0.317 | 0.382 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 16.965 | 14.377 | 14.69 | 15.277 | 9.912 | 9.543 | 7.537 | 7.665 | 7.432 | 3.702 | 2.307 |
| General & Administrative Expenses
| 0 | 9.168 | 9.465 | 10.314 | 7.565 | 5.878 | 4.887 | 4.72 | 4.205 | 4.386 | 1.95 |
| Selling & Marketing Expenses
| 0 | 9.453 | 8.468 | 7.652 | 4.86 | 2.135 | 3.004 | 3.122 | 0 | 0 | 0 |
| SG&A
| 23.134 | 18.621 | 17.933 | 17.966 | 12.425 | 8.013 | 7.891 | 7.842 | 4.205 | 4.386 | 1.95 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0.004 | 0.004 | 0.002 | 0 | 0.082 |
| Operating Expenses
| 40.099 | 32.998 | 32.623 | 33.243 | 22.337 | 17.557 | 15.432 | 15.51 | 11.638 | 8.087 | 4.339 |
| Operating Income
| -33.062 | -28.616 | -29.602 | -30.291 | -18.863 | -15.133 | -14.827 | -17.627 | -15.64 | -11.223 | -4.339 |
| Operating Income Ratio
| -3.096 | -3.975 | -4.431 | -4.407 | -2.583 | -3.576 | -7.76 | -4.519 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 6.58 | -0.081 | 3.744 | -0.303 | 2.425 | -0.171 | -0.248 | 2.718 | -0.672 | -1.101 | -3.598 |
| Income Before Tax
| -26.482 | -28.697 | -28.382 | -30.594 | -21.577 | -15.31 | -15.075 | -14.909 | -12.137 | -12.324 | -7.937 |
| Income Before Tax Ratio
| -2.48 | -3.986 | -4.248 | -4.451 | -2.954 | -3.618 | -7.89 | -3.823 | 0 | 0 | 0 |
| Income Tax Expense
| -0.002 | -0.128 | 0.287 | 0.105 | 0.045 | 0.148 | 0.169 | 0.059 | 0.01 | -0.523 | 0.41 |
| Net Income
| -26.48 | -28.569 | -28.669 | -30.699 | -21.622 | -15.458 | -15.244 | -14.968 | -12.147 | -11.801 | -8.204 |
| Net Income Ratio
| -2.479 | -3.968 | -4.291 | -4.467 | -2.96 | -3.653 | -7.979 | -3.838 | 0 | 0 | 0 |
| EPS
| -1.12 | -1.35 | -1.38 | -1.5 | -1.25 | -1.39 | -1.52 | -2.44 | -2.93 | -4.98 | -37.86 |
| EPS Diluted
| -1.12 | -1.35 | -1.38 | -1.5 | -1.25 | -1.39 | -1.52 | -2.44 | -2.93 | -4.98 | -37.86 |
| EBITDA
| -33.062 | -26.781 | -34.635 | -28.648 | -19.496 | -12.526 | -13.242 | -16.778 | -15.563 | -11.148 | -6.314 |
| EBITDA Ratio
| -3.096 | -3.72 | -5.184 | -4.168 | -2.669 | -2.96 | -6.931 | -4.302 | 0 | 0 | 0 |